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Chemokines and their receptors control cell migration during development, immune system responses, and in numerous diseases, including inflammation and cancer. The structural basis of receptor:chemokine recognition has been a long-standing unanswered question due to the challenges of structure determination for membrane protein complexes. Here, we report the crystal structure of the chemokine receptor CXCR4 in complex with the viral chemokine antagonist vMIP-II at 3.1 angstrom resolution. The structure revealed a 1:1 stoichiometry and a more extensive binding interface than anticipated from the paradigmatic two-site model. The structure helped rationalize a large body of mutagenesis data and together with modeling provided insights into CXCR4 interactions with its endogenous ligand CXCL12, its ability to recognize diverse ligands, and the specificity of CC and CXC receptors for their respective chemokines.
T he chemokine receptor CXCR4 controls cell migration during immune surveillance and development of the cardiovascular, hematopoietic, and central nervous systems (1) (2) (3) . Like many other chemokine receptors (CKRs), CXCR4 contributes to inflammatory diseases and cancer (4, 5) . It also functions as one of two coreceptors that facilitate entry of HIV into host immune cells (6) . Despite the importance of CXCR4 and CKRs in general, structural insights into CKR: chemokine recognition have been limited to nuclear magnetic resonance studies of chemokines with peptides derived from CKR N termini (7) (8) (9) . This is partly due to the challenges of structure determination for full-length membrane proteins and their complexes.
Here, we present the structure of CXCR4 in complex with vMIP-II, a CC chemokine encoded by Kaposi's sarcoma-associated herpesvirus. vMIP-II functions as a broad-spectrum antagonist of many human CKRs (10) and helps the virus to escape the host immune response (11) . We chose vMIP-II for structural studies because it is a high-affinity antagonist of CXCR4 [median inhibitory concentration, 6 to 15 nM (10, 12)] and, as a ligand for both CC and CXC chemokine receptors, was expected to provide insight into ligand recognition specificity.
Design of an irreversible CXCR4:vMIP-II complex
Despite high affinity in membranes, the CXCR4: vMIP-II complex was insufficiently stable in detergent to justify crystallization trials. We therefore employed a strategy that uses disulfide trapping to generate an irreversible complex (13, 14) . Coexpression of pairs of single cysteine mutants of CXCR4 and vMIP-II was expected to result in spontaneous formation of a disulfide bond if the disulfide was compatible with the native geometry of the CKR:chemokine complex. Guided by threedimensional models of CXCR4:chemokine complexes (14), 37 cysteine mutant pairs were designed, and, for each pair, the abundance of disulfidetrapped complexes was evaluated (15) . These pairs included seven N-terminal cysteine mutants of vMIP-II that were systematically coexpressed with two CXCR4 cysteine mutants, D97 2.63 C or D187 ECL2 C [superscript denotes the BallesterosWeinstein index (16, 17) for helical domain residues; ECL is extracellular loop]. Of all mutant pairs analyzed, CXCR4(D187C) coexpressed with vMIP-II(W5C) formed the highest percentage of trapped complex (Fig. 1A) . It also showed an unfolding temperature of 63°C (Fig. 1B) , which is 4°to 14°C higher than other mutant combinations, and excellent monodispersity when analyzed by size-exclusion chromatography ( fig. S1 ). By comparison, the mutant pair with the second highest melting temperature, CXCR4(D187C): vMIP-II(H6C) (59°C), was produced in significantly lower yield and showed lower monodispersity, despite the adjacent position of the vMIP-II cysteine ( fig. S1 ). CXCR4(D97C) formed little or no covalent complex with any of the seven vMIP-II mutants tested (Fig. 1, A and B) . The observed sensitivity of several biophysical properties of the complex to precise cysteine placement suggests specificity of the disulfidetrapping approach and supports compatibility of the D187C:W5C disulfide bond with the native complex geometry. We therefore selected CXCR4(D187C):vMIP-II(W5C) for crystallization in lipidic cubic phase (LCP) (18) and determined the structure at 3.1 Å resolution. Data collection and refinement statistics are shown in table S1.
Overall complex geometry
In complex with vMIP-II, CXCR4 possesses the typical seven transmembrane (TM) helical topology. Whereas previous dimeric structures of CXCR4 suggested that chemokines might bind receptors in a 2:1 CKR:chemokine stoichiometry (19, 20) , the present structure demonstrates that the stoichiometry is 1:1, in agreement with a recent study (14) . The chemokine interacts via its globular core with the receptor N terminus [chemokine recognition site 1 (CRS1) (21) ] and via its N terminus with the receptor TM pocket (CRS2) (Fig. 1C) . Clear electron density is observed for the entire chemokine N terminus, including the CXCR4(D187C):vMIP-II(W5C) disulfide bond, which adopts a favorable geometry (Fig.  1D) . Residues 1 to 22 of the receptor are not visible in the density, consistent with the moderate stability of the CRS1 interaction between CXCR4 and vMIP-II, as suggested by disulfide-trapping experiments ( fig. S2 ) and previous mutagenesis studies (12) .
Molecular interactions between CXCR4 and vMIP-II
The CXCR4:vMIP-II interaction is mediated by an extensive (1330 Å 2 ) contiguous interface, with every residue in the chemokine N terminus and N loop (1-LGASCHRPDKCCLGYQ-16) contacting the receptor ( Fig. 2 and table S2 ). Although parts of the interface can be classified as CRS1 or CRS2, the absence of a distinct boundary prompted introduction of an intermediate region, CRS1.5 (Fig.  2, A and B) . The CRS1 interaction involves CXCR4 N-terminal residues 23-SMKEP-27 packing against the chemokine N loop (residues 13-LGYQ-16) and its third b strand (b 3 , residues 49-QVC-51) (Fig. 2 , C and D, and table S2). This interaction continues toward CRS1.5, where receptor residues 27-PCFRE-31 bind to chemokine residues 8-PDKCC-12 ( Fig.  2 , C and D) and form an antiparallel b sheet. In CRS2, the chemokine N terminus makes hydrogen bonds to receptor residues D97 2.63 , D262 6.58 , and E288
7.39 and numerous van der Waals packing interactions (Fig. 2 , C and D, and table S2). Most of the interacting CXCR4 residues are known determinants of either vMIP-II binding (table S3) or CXCL12 binding and activation (22) (23) (24) (25) (26) . The dominant role of the vMIP-II N terminus is supported by the fact that an isolated vMIP-II(1-21) peptide binds CXCR4 with appreciable affinity [190 nM (12) versus 6 to 15 nM for wild-type (WT) vMIP-II (10, 12)], which is dramatically reduced by mutations L1A, R7A, and K10A (27) (table S3) . Notably, a W5A mutation has only a moderate effect (27) . Disulfide-trapping studies also support the role of the chemokine N loop ( fig. S2 ).
Comparison of CXCR4:vMIP-II with previous structures
The conformation of the observed part of the receptor N terminus differs significantly from previous small-molecule and peptide-bound structures (19) in that it adopts an orientation almost perpendicular to the membrane to form a b-sheet interaction in CRS1.5 with chemokine residues C11 and C12 (Fig. 3, A and B) . To accommodate this change as well as binding of the chemokine N terminus in the TM pocket, the extracellular half of helix I is laterally shifted outward by~2.4 Å, forming an extra a-helical turn and bending at the top (Fig. 3A) . ECL2 forms a b hairpin as in other CXCR4 structures but is more closed onto the binding pocket (Fig. 3A) , bringing D181 and D182 of CXCR4 in close proximity with K10 of vMIP-II (Fig. 2, C and D) .
The binding pocket of CXCR4 is open and negatively charged (Fig. 3C ) and can be separated into a major and minor subpocket (28) . Similar to the small-molecule antagonist, IT1t, the chemokine N terminus makes the majority of contacts in the minor subpocket and makes polar interactions with D97
2.63 and E288 7.39 (Fig. 3,  C and D) . By contrast, the spatial overlap between the vMIP-II N terminus and CVX15 is moderate, with common recognition determinants including D187 ECL2 and D262 6.58 (Fig. 3, C and E). The limited overlap between CVX15 and the chemokine N terminus may enable the design of modulators that simultaneously occupy the minor and major subpockets; in fact, a series of CXCR4 ligands obtained by grafting the N terminus of CXCL12 onto a peptide analog of CVX15 (29) may bind CXCR4 in this manner.
As in five earlier structures (19) , CXCR4 forms a dimer in the vMIP-II-bound form (Fig. 4A) . The preservation of similar dimerization patterns in all CXCR4 structures (Fig. 4B) suggests possible physiological relevance and is consistent with numerous reports of CXCR4 homo-and heterodimerization in cells (30) . The structure also suggests that a receptor dimer can accommodate two monomeric chemokine ligands.
Structure comparisons, bioinformatics, and homology modeling insights into the specificity of CC and CXC chemokine recognition by CKRs With the exception of atypical CKRs, human CC and CXC chemokines generally pair exclusively with CKRs from the same subfamily. To gain insight into this specificity, as well as the noncanonical pairing of a human CXC receptor (CXCR4) with a viral CC chemokine (vMIP-II), structural and sequence analyses ( fig. S4 ) were complemented by molecular modeling (15) . A complex between CXCR4 and its endogenous CXC chemokine, CXCL12, as well as a complex between vMIP-II and another human CKR, CCR5, were chosen for analysis due to available structural and mutagenesis information. An initial systematic analysis of chemokine structures revealed conformational differences between CC and CXC motifs of the respective chemokines: Whereas in CC chemokines, this region is straight and forms b-sheet interactions within chemokine dimers, it is bent in CXC chemokines and forms no substantial protein-protein interface contacts ( fig. S4A ). This difference is reflected in the CRS1.5 interactions of the structure and the modeled complexes (Fig. 5, A to C) . In the CXCR4:CXCL12 model (Fig. 5A) , the bend directs the chemokine N terminus toward receptor helices V/VI and enables hydrogen bonding between chemokine R8 (highly conserved as a base in CXC but not CC chemokines) ( fig. S4B ) and receptor D262 6 .58 (highly conserved as an acid in CXC but not CC CKRs) ( fig. S4C ). By contrast, in the CCR5:vMIP-II model (Fig. 5C) , the straightened conformation of the chemokine CC motif directs the chemokine N terminus along the receptor N terminus toward helix I, aided by interactions with receptor K22 in position C+2 (where C is the conserved N-terminal cysteine) and with D276 7.32 . Notably a base in position C+2 and an acid in position 7.32 are both highly conserved in CC but not CXC CKRs ( fig. S4C ). Furthermore, mutation of K22 or D276 7.32 in CCR5 abrogates binding to vMIP-II, CCL3, and CCL5 (31). Interestingly, both vMIP-II and CXCR4 possess features that are atypical for their respective classes; vMIP-II has three basic residues (H6, R7, and K10) in its proximal N terminus ( fig. S4B) , and CXCR4 has a base (R30) at C+2 ( fig. S4C ), which may partially explain the unusual coupling between CXCR4 and vMIP-II.
Relevant differences between CC and CXC families are also observed in the predicted CRS1 interactions. The presence of sulfotyrosines sY14 and sY15 (32) in proximity of the conserved N-terminal cysteine in CCR5 ( fig. S4C) facilitates interactions with basic residues in the vMIP-II N loop (K17 and R18) and b 2 -b 3 loop (R46 and R48) (Fig. 5C ). When evaluated family-wide, high acidity and sulfotyrosine content of the proximal N terminus are characteristic of CC but not CXC receptors ( fig. S4C ), whereas the basic nature of N and b 2 -b 3 loops distinguishes CC from CXC chemokines ( fig. S4B ). It appears therefore, that even when sulfotyrosines in the N terminus of CXC receptors contribute to chemokine affinity, they do not engage the N or b 2 -b 3 loops of CXC chemokines. Consistent with this notion, CXCR4 sY21 is predicted to interact with the CXCL12 N-loop-b 1 -strand junction (Fig. 5A ) instead of the neutral N and b 2 -b 3 loops, similar to positions of sulfate groups in multiple CXCL12 structures (33, 34) . The cleft defined by the N and b 2 -b 3 loops of CXCL12 is occupied by the backbone of CXCR4 residues S23 to M24, which closely mimic the interaction of a small-molecule CXCR4: CXCL12 inhibitor (34) . CXCR4 is a rare CXC receptor that possesses a sulfotyrosine in the proximal N terminus (position C-7) ( fig. S4C ), which may explain its ability to engage a CC chemokine (vMIP-II) via its basic N or b 2 -b 3 loops. This engagement is further assisted by a fourresidue epitope in the chemokine b 3 -strand that is SCIENCE sciencemag.org (table S2) .
strictly conserved between vMIP-II (48-RQVC-51) and CXCL12 (47-RQVC-50) and that interacts with receptor D22 and E26 (Fig. 5B) , both of which are important for vMIP-II and CXCL12 recognition (23, 26) .
The CXCR4:vMIP-II structure can also explain why CXC (35) but not CC (36) chemokines bind and activate their receptors as dimers. CC chemokines dimerize by b-sheet interactions between the straight CC motifs and N-terminal residues (Fig. 6A) . This largely coincides with the CRS1.5 interaction in the CXCR4:vMIP-II structure, making it sterically impossible for a CC chemokine to simultaneously bind its dimer partner and a receptor (Fig. 6B) . By contrast, CXC chemokines dimerize by their b 1 strands (Fig. 6C) , which are not involved in receptor interactions and therefore are compatible with the geometry of the CKR: chemokine complexes (Fig. 6D) . This model also suggests that CXC chemokine dimers likely bind to single receptor subunits (Fig. 6E) and not to both subunits in a dimer as previously hypothesized (37).
Modeling-based insights into agonist versus antagonist chemokine binding to CXCR4 CXCL12 can be converted into a potent antagonist of CXCR4 by as little as a single N-terminal amino-acid substitution (P2G) (38) . To investigate the basis for this notable change in pharmacology, modeling of CRS2 interactions for both CXCL12 and CXCL12(P2G) with CXCR4 was performed. With both chemokine variants, the four distal N-terminal residues were predicted to bind in the minor subpocket of CXCR4 in a manner similar to vMIP-II (Fig. 5, D and E) . The N-terminal and sidechain amines of chemokine K1 were predicted to form hydrogen bonds to receptor residues D97 2.63 and E288 7.39 , respectively, whereas chemokine residues S4 (in CXCL12) and Y7 [in both CXCL12 and CXCL12(P2G)] hydrogen-bond to D187 ECL2 . Notably, K1 in CXCL12 and D97 2.63 , D187
ECL2
, and E288 7.39 in CXCR4 are all critical for receptor interaction and activation (22, 25, 26, 38) . In CXCL12, the side chain of P2 was found in proximity of receptor residue Y116 3.32 (Fig. 5D) , whose direct interaction with agonists is frequently involved in activation of GPCRs (39) . By contrast, due to its greater flexibility and smaller steric volume, the G2 to S4 region of CXCL12(P2G) packed differently (Fig. 5E) , avoiding interaction with Y116 3.32 and potentially explaining the inability of CXCL12(P2G) to activate CXCR4. However, because docking was performed with an inactive receptor conformation, further structural studies will be necessary to fully understand activation mechanisms.
Chemokine receptor plasticity, promiscuity, and implications for drug design CXCR4 is remarkable in its ability to recognize multiple unrelated small molecules, peptides, and proteins. While engaging a conserved set of binding determinants, the ligands occupy different regions of the binding pocket due to receptor conformational plasticity involving receptor sidechain and backbone adjustments. Such versatility may allow the receptor to accommodate ligands of different classes, including both CC-and CXCtype chemokines as well as allosteric inhibitors. The growing number of chemokine receptor SCIENCE sciencemag.org structures with different ligands opens possibilities for rational design of ligands that have improved inhibition profiles and mechanisms of action. 
